Brief: Xbrane Biopharma Q2 EBITDA Loss Narrows To SEK 28.4 Mln

Xbrane Biopharma AB

22/07/2022 07:09

July 22 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * XBRANE BIOPHARMA RELEASES INTERIM REPORT FOR JANUARY –
JUNE 2022
    * Q2 EBITDA LOSS SEK 28.4 MILLION VERSUS LOSS SEK 53.8
MILLION
YEAR AGO
    * Q2 REVENUE SEK 15.6 MILLION VERSUS SEK 2.5 MILLION YEAR
AGO

Source text for Eikon:  ID:nMFN3NJZC4 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))